PT  - JOURNAL ARTICLE
AU  - CHIN-MU HSU
AU  - MEI-DUE YANG
AU  - CHIA-WEN TSAI
AU  - CHIEN-YI HO
AU  - WEN-SHIN CHANG
AU  - SHENG-CHI CHANG
AU  - LONG-BIN JENG
AU  - YUHSIN TSAI
AU  - FUU-JEN TSAI
AU  - DA-TIAN BAU
TI  - The Contribution of <em>Caveolin-1</em> Genotype and Phenotype to Hepatocellular Carcinoma
DP  - 2013 Feb 01
TA  - Anticancer Research
PG  - 671--677
VI  - 33
IP  - 2
4099  - http://ar.iiarjournals.org/content/33/2/671.short
4100  - http://ar.iiarjournals.org/content/33/2/671.full
SO  - Anticancer Res2013 Feb 01; 33
AB  - Background: Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors worldwide, for which the prevalence and mortality rates are very high in Taiwan. Caveolin-1 (CAV-1) is a main structural protein of caveolae and plays a regulatory role in signaling pathways and tumorigenesis. High expression of Cav-1 in mouse HCC is positively correlated with higher cell invasive capacity, but the contribution of CAV-1 genetic variants during HCC progression is still largely unknown. In this study, we investigated the contribution of CAV-1 variant to the risk of HCC from the analyses of DNA, RNA and proteins. Materials and Methods: We enrolled 298 patients with HCC and 298 cancer-free controls, frequency-matched by age and gender in this case–control study. Firstly, the associations of six single nucleotide polymorphisms (SNPs) of the Cav-1 gene at C521A (rs1997623), G14713A (rs3807987), G21985A (12672038), T28608A (rs3757733), T29107A (rs7804372), and G32124A (rs3807992) with HCC risk in a Taiwanese population were evaluated. Secondly, thirty HCC tissue samples with variant genotypes were tested to estimate for CAV-1 mRNA expression by real-time quantitative reverse transcription. Finally, the HCC tissue samples of variant genotypes were examined by western blotting to estimate their CAV-1 protein expression patterns. Results: There were significant differences between the HCC and control groups in the distributions of the CAV-1 G14713A genotypes (p=0.0124), and these carrying AG and AA genotypes had a higher risk for HCC, compared with those with the GG genotype (odds ratio=1.51 and 1.94, respectively). Patients with CAV-1 G14713A AG or AA genotype had higher levels of mRNA (p=0.0001) and protein (p=0.0019) than those with the GG genotype. Conclusion: Our multi-approach findings at the DNA, RNA and protein levels suggest that CAV-1 may play a critical role in HCC carcinogenesis, and serve as a target for HCC therapy.